Conference Coverage: ASCO GU 2023 Highlights

Expert perspectives and strategic insights on the latest therapeutic developments in GU cancer treatment from the 2023 ASCO GU Cancers Symposium, and implications on individualized clinical decision-making.

February 24, 2023
Daniel Petrylak, MD, Yale, Aptitude Health


Daniel Petrylak, MD

Yale Cancer Center, New Haven, CT, USA

Faculty Members

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, USA

Karim Fizazi, MD, PhD
Gustave Roussy, Villejuif, France

Leonard Gomella, MD
Sidney Kimmel Cancer Center, Philadelphia, PA, USA

Thomas Powles, MD, MBBS, MRCP
Barts Cancer Centre, London, United Kingdom

Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Joaquim Bellmunt, MD, PhD
Harvard Medical School, Boston, MA, USA

Sample Report

Start discovering the insights

View Report


A report will be produced that is based on the meeting, and will discuss the following topics

  • Prostate Cancer Part 1 – Hormonal Therapies and Chemotherapies
  • Prostate Cancer Part 2 – Targeted Therapies
  • Bladder Cancer Part 1 – ADCs
  • Bladder Cancer Part 2 – PARP Inhibitors and Immunotherapies
  • Renal Cell Carcinoma

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.